Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, Guangdong, PR China.
Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210008, PR China.
Aging (Albany NY). 2023 Nov 27;15(22):13345-13367. doi: 10.18632/aging.205246.
Neuroblastoma (NB) is a childhood cancer originating from immature nerve cells in the sympathetic nervous system. Current clinical and molecular subtyping methods for NB have limitations in providing accurate prognostic information and guiding treatment decisions.
To overcome these challenges, we explored the microenvironment of NB based on the knowledge-based functional gene expression signatures (Fges), which revealed heterogeneous subtypes. Consensus clustering of Fges activity scores identified three subtypes (Cluster 1, Cluster 2, and Cluster 3) that demonstrated significant differences in prognosis compared to mainstream subtypes. We assessed the immune infiltration, immunogenicity, CD8T cytotoxicity, and tumor purity of these subtypes, uncovering their distinct biological functions. Cluster 1 and Cluster 2 exhibited higher immunoreactivity, while Cluster 3 displayed higher tumor purity and poor prognosis. Gene ontology annotation and pathway analysis identified immune activation in Cluster 1, epithelial-mesenchymal transition (EMT) in Cluster 2, and cell cycle processes in Cluster 3. Notably, the impact of EMT activity on prognosis may vary across NB subtypes. A classification model using XGBoost accurately predicted subtypes in independent NB cohorts, with significant prognostic differences. , , and emerged as potential therapeutic targets in Cluster 3. inhibitors showed subtype-specific responses, suggesting tailored treatment strategies. Single-cell analysis highlighted unfavorable clinical features in Cluster 3, including high-risk classification and reduced cytotoxicity. Suppressed interactions between monocytes, macrophages, and regulatory T cells were observed, affecting immune regulation and patient prognosis.
To summarize, we have identified a new independent prognostic factor in NB that underscores the significant correlation between tumor phenotype and immune contexture. These findings deepen our understanding of NB subtypes and immune cell interactions, paving the way for more effective treatment approaches.
神经母细胞瘤(NB)是一种起源于交感神经系统未成熟神经细胞的儿童癌症。目前用于 NB 的临床和分子亚型方法在提供准确的预后信息和指导治疗决策方面存在局限性。
为了克服这些挑战,我们基于基于知识的功能基因表达特征(Fges)探索了 NB 的微环境,这揭示了异质亚型。Fges 活性评分的共识聚类确定了三个与主流亚型相比具有显著预后差异的亚型(Cluster 1、Cluster 2 和 Cluster 3)。我们评估了这些亚型的免疫浸润、免疫原性、CD8T 细胞毒性和肿瘤纯度,揭示了它们不同的生物学功能。Cluster 1 和 Cluster 2 表现出更高的免疫反应性,而 Cluster 3 则表现出更高的肿瘤纯度和较差的预后。基因本体注释和通路分析鉴定了 Cluster 1 中的免疫激活、Cluster 2 中的上皮-间充质转化(EMT)和 Cluster 3 中的细胞周期过程。值得注意的是,EMT 活性对预后的影响可能因 NB 亚型而异。使用 XGBoost 的分类模型准确预测了独立的 NB 队列中的亚型,具有显著的预后差异。、和 成为 Cluster 3 中的潜在治疗靶点。 抑制剂显示出亚型特异性反应,表明需要制定量身定制的治疗策略。单细胞分析突出了 Cluster 3 中的不利临床特征,包括高危分类和降低的细胞毒性。观察到单核细胞、巨噬细胞和调节性 T 细胞之间的相互作用受到抑制,这影响了免疫调节和患者的预后。
总之,我们在 NB 中确定了一个新的独立预后因素,强调了肿瘤表型与免疫组织之间的显著相关性。这些发现加深了我们对 NB 亚型和免疫细胞相互作用的理解,为更有效的治疗方法铺平了道路。